Janssen and Second Genome Partner on Microbiome Drug Discovery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Janssen and Second Genome Partner on Microbiome Drug Discovery


Janssen Biotech and Second Genome have entered into an agreement to focus on microbiome drug discovery, Second Genome announced in a press release. With the goal of advancing novel drug targets, the agreement is focused on therapeutic mechanisms in ulcerative colitis mediated by the bacterial ecosystem living within the human gut, referred to as the microbiome. Second Genome will apply its microbiome modulation discovery platform to characterize the role of bacterial populations in ulcerative colitis. 

The microbiome is an emerging area of interest involving research, such as the National Institute of Health’s Human Microbiome Project, to evaluate the symbiotic relationship that bacteria have developed in the human body. “Foundational microbiome research over the past several years has demonstrated that alterations to the microbiome are central to the development of inflammation and metabolic disorders,” said Peter DiLaura, president and CEO at Second Genome, in the press release. “The role of the microbiome in health and disease has arrived as a significant area of focus in pharmaceutical R&D. This collaboration with Janssen will identify mechanisms by which microbial populations in the gut have an impact in ulcerative colitis.”

Under the terms of the agreement, Second Genome will receive an upfront payment and support for research activities conducted by Second Genome in collaboration with Janssen. In addition, Second Genome is eligible to receive potential payments upon the achievement of certain research milestones. The research will be funded through the Johnson & Johnson Innovation Center and the Immunology Therapeutic Area within Janssen Research & Development.

In May, 2013, Janssen Biotech received FDA approval for its SIMPONI (golimumab) subcutaneously administered anti-tumor necrosis factor (TNF)-alpha therapy for moderately to severely active ulcerative colitis in adult patients who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral treatments. Ulcerative colitis has had limited treatment options.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here